Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Everolimus in patients with autosomal dominant polycystic kidney disease.

Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU.

N Engl J Med. 2010 Aug 26;363(9):830-40. doi: 10.1056/NEJMoa1003491. Epub 2010 Jun 26. Erratum in: N Engl J Med. 2010 Sep 16;363(12):1190. N Engl J Med. 2010 Nov 11;363(20):1977.

2.

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.

Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP.

N Engl J Med. 2010 Aug 26;363(9):820-9. doi: 10.1056/NEJMoa0907419. Epub 2010 Jun 26.

3.

mTOR inhibitors in polycystic kidney disease.

Watnick T, Germino GG.

N Engl J Med. 2010 Aug 26;363(9):879-81. doi: 10.1056/NEJMe1006925. Epub 2010 Jun 26. No abstract available.

PMID:
20581393
4.

mTOR inhibitors and autosomal dominant polycystic kidney disease.

Levey AS, Stevens LA.

N Engl J Med. 2011 Jan 20;364(3):287; author reply 287-9. doi: 10.1056/NEJMc1010845#SA2. No abstract available.

PMID:
21247327
5.

mTOR inhibitors and autosomal dominant polycystic kidney disease.

Braun WE.

N Engl J Med. 2011 Jan 20;364(3):287; author reply 287-8. doi: 10.1056/NEJMc1010845#SA3. No abstract available.

PMID:
21247326
6.

mTOR inhibitors and autosomal dominant polycystic kidney disease.

Grantham JJ, Bennett WM, Perrone RD.

N Engl J Med. 2011 Jan 20;364(3):286-7; author reply 287-9. doi: 10.1056/NEJMc1010845#SA1. No abstract available.

PMID:
21247328
7.

Sirolimus therapy to halt the progression of ADPKD.

Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, Ondei P, Rubis N, Diadei O, Gherardi G, Prandini S, Panozo A, Bravo RF, Carminati S, De Leon FR, Gaspari F, Cortinovis M, Motterlini N, Ene-Iordache B, Remuzzi A, Remuzzi G.

J Am Soc Nephrol. 2010 Jun;21(6):1031-40. doi: 10.1681/ASN.2009121302. Epub 2010 May 13.

8.

Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.

Wüthrich RP, Kistler AD, Serra AL.

Transplant Proc. 2010 Nov;42(9 Suppl):S44-6. doi: 10.1016/j.transproceed.2010.07.008. Review.

PMID:
21095452
9.

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP.

Nephrol Dial Transplant. 2006 Mar;21(3):598-604. Epub 2005 Oct 12.

10.

Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.

Ponticelli C, Locatelli F.

Nephrol Dial Transplant. 2010 Dec;25(12):3809-12. doi: 10.1093/ndt/gfq527. Epub 2010 Aug 26. No abstract available.

11.

Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial.

Riegersperger M, Herkner H, Sunder-Plassmann G.

Trials. 2015 Apr 23;16:182. doi: 10.1186/s13063-015-0692-3.

12.

Do mTOR inhibitors still have a future in ADPKD?

Perico N, Remuzzi G.

Nat Rev Nephrol. 2010 Dec;6(12):696-8. doi: 10.1038/nrneph.2010.153. No abstract available.

PMID:
21109768
13.

Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?

Canaud G, Knebelmann B, Harris PC, Vrtovsnik F, Correas JM, Pallet N, Heyer CM, Letavernier E, Bienaimé F, Thervet E, Martinez F, Terzi F, Legendre C.

Am J Transplant. 2010 Jul;10(7):1701-6. doi: 10.1111/j.1600-6143.2010.03152.x.

14.
15.
16.

Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.

Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wüthrich RP, Serra AL.

Am J Physiol Renal Physiol. 2009 Dec;297(6):F1597-605. doi: 10.1152/ajprenal.00430.2009. Epub 2009 Sep 23.

17.

Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment.

Soliman A, Zamil S, Lotfy A, Ismail E.

Transplant Proc. 2012 Dec;44(10):2936-9. doi: 10.1016/j.transproceed.2012.06.073.

PMID:
23195001
18.

[Autosomal dominant polycystic kidney disease].

Horie S.

Nihon Jinzo Gakkai Shi. 2011;53(1):6-9. Review. Japanese. No abstract available.

PMID:
21370570
19.

Mammalian target of rapamycin and autosomal dominant polycystic kidney disease.

Wüthrich RP, Serra AL.

Transplant Proc. 2009 Jul-Aug;41(6 Suppl):S18-20. doi: 10.1016/j.transproceed.2009.06.097. Epub 2009 Jul 10.

PMID:
19651290
20.

Therapeutic interventions for autosomal dominant polycystic kidney disease.

Edelstein CL.

Nephrol News Issues. 2008 Mar;22(3):25-6.

PMID:
18372677
Items per page

Supplemental Content

Write to the Help Desk